Ignite Creation Date:
2024-05-06 @ 12:49 PM
Last Modification Date:
2024-10-26 @ 1:04 PM
Study NCT ID:
NCT03858972
Status:
TERMINATED
Last Update Posted:
2021-07-30
First Post:
2019-02-26
Brief Title:
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative HR Positive LAMBC
Sponsor:
Odonate Therapeutics Inc
Organization:
Odonate Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Taxane | View |
| Tesetaxel | View |
| Capecitabine | View |
| HER2 negative | View |
| Combination of tesetaxel and capecitabine | View |
| Taxane-naive | View |
| Locally advanced or metastatic breast cancer | View |
| Hormone receptor positive | View |
| Metastatic breast cancer MBC | View |
| Breast cancer | View |
| Central nervous system CNS metastases | View |
| de novo metastatic breast cancer | View |
| Oral chemotherapy | View |